---
title: Update Breast Cancer 2023 Part 1 - Early Stage Breast Cancer
date: '2023-11-02'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37916183/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231102180753&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: With abemaciclib (monarchE study) and olaparib (OlympiA study) gaining
  approval in the adjuvant treatment setting, a significant change in the standard
  of care for patients with early stage breast cancer has been established for some
  time now. Accordingly, some diverse developments are slowly being transferred from
  the metastatic to the adjuvant treatment setting. Recently, there have also been
  positive reports of the NATALEE study. Other clinical studies are currently investigating
  ...
disable_comments: true
---
With abemaciclib (monarchE study) and olaparib (OlympiA study) gaining approval in the adjuvant treatment setting, a significant change in the standard of care for patients with early stage breast cancer has been established for some time now. Accordingly, some diverse developments are slowly being transferred from the metastatic to the adjuvant treatment setting. Recently, there have also been positive reports of the NATALEE study. Other clinical studies are currently investigating ...